AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR BEMARITUZUMAB IN FIBROBLAST GROWTH FACTOR RECEPTOR 2b (FGFR2b) POSITIVE FIRST-LINE GASTRIC CANCER ...

Key Players: Major companies in the protein therapeutics market include Amgen Inc., Pfizer Inc., Genentech USA Inc. and Eli ...

While Amgen’s monthly obesity candidate MariTide helped patients lose significant amounts of weight in a phase 2 study, prevalent gastrointestinal side effects are leading the company to use a ...

Discover the top 17 tech PR agencies offering PR services for technology and IT brands to boost visibility, reputation, and global reach.

Amgen (AMGN) closed the most recent trading day at $297, moving +1.38% from the previous trading session.

Amgen (NASDAQ:AMGN) today announced full results from Part 1 of the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133), a long-acting, peptide-antibody conjugate subcutaneously ...

The ROR inhibitors market is witnessing steady growth driven by the increasing understanding of receptor tyrosine kinase-like orphan receptor ...

Amgen (AMGN) Stock Slides as Market Rises: Facts to Know Before You Trade June 23, 2025 — 06:00 pm EDT Written by Zacks Equity Research for Zacks -> ...

A 333-unit community, Hillcrest Apartments, will be developed directly across from Amgen’s headquarters in Thousand Oaks, California, by The Latigo Group.

Amgen (AMGN) closed the most recent trading day at $296.85, moving +2.18% from the previous trading session. This change outpaced the S&P 500's 0.48% gain on the day. Elsewhere, the Dow saw a ...

The global Biosimilars Market , valued at US$32.75 billion in 2024 stood at US$35.04 billion in 2025 and is projected to ...